Atea Pharmaceuticals Inc.

12/04/2024 | Press release | Distributed by Public on 12/04/2024 14:50

7th Annual Evercore HealthCONx Conference - Phase 2 Open Label Study of Bemnifosbuvir + Ruzasvir